title: Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses.
abstract: Conditionally replicating adenoviruses (CRAds) represent a promising modality for the treatment of neoplastic diseases, including Prostate Cancer. Selectively replicating viruses can be generated by placing a tissue or cancer-specific promoter upstream of one or more of the viral genes required for replication (for example, E1A, E1B). We have previously reported multiple cellular processes that can attenuate viral replication, which in turn compromises viral oncolysis and tumor kill. In this study, we investigated the importance of the cyclin-dependent kinase inhibitor p21/Waf-1, on viral replication and tumor growth. To our knowledge, this is the first report describing the importance of p21/Waf-1shRNA on the induction of an androgen responsive element (ARE) based promoter driving the E1A gene. As a proof of concept, the study emphasizes the use of RNA interference technology to overcome promoter weaknesses for tissue-specific oncolytic viruses, as well as the cellular inhibitor pathways on viral life cycle. Using RNA interference against p21/Waf-1, we were able to show an increase in viral replication and viral oncolysis of prostate cancer cells. Similarly, CRAd viruses that carry p21/Waf-1 shRNA (Ad5-RV004.21) were able to prevent tumor outgrowth that resulted in a marked increase in the mean survival time of tumor-bearing mice compared with CRAd without p21/Waf-1 shRNA (Ad5-RV004). In studies combining Ad5-RV004.21 with Adriamycin, a suprar-additive effect was observed only in CRAds that harbor shRNA against p21/Waf-1. Taken together, these findings of enhanced viral replication in prostate cancer cells by using RNA interference against the cdk inhibitor p21/Waf-1 have significant implications in the development of prostate-specific CRAd therapies.
authors.affiliation: Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287-2101, USA.
authors.forename: N
authors.initials: N
authors.lastname: Höti
authors.forename: W H
authors.initials: WH
authors.lastname: Chowdhury
authors.forename: S
authors.initials: S
authors.lastname: Mustafa
authors.forename: J
authors.initials: J
authors.lastname: Ribas
authors.forename: M
authors.initials: M
authors.lastname: Castanares
authors.forename: T
authors.initials: T
authors.lastname: Johnson
authors.forename: M
authors.initials: M
authors.lastname: Liu
authors.forename: S E
authors.initials: SE
authors.lastname: Lupold
authors.forename: R
authors.initials: R
authors.lastname: Rodriguez
mesh_terms: D000256:Adenoviridae / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D000818:Animals; D045744:Cell Line, Tumor; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics*; D015536:Down-Regulation; D004317:Doxorubicin / Q000494:pharmacology; D055785:Gene Knockdown Techniques; D020868:Gene Silencing; D005822:Genetic Vectors / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D050504:Oncolytic Viruses / Q000235:genetics* / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy* / Q000821:virology; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics*; D011944:Receptors, Androgen / Q000096:biosynthesis / Q000235:genetics; D014779:Virus Replication / Q000235:genetics / Q000502:physiology
chemical_list: C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D034741:RNA, Small Interfering; D011944:Receptors, Androgen; D004317:Doxorubicin
references.citation: J Urol. 2008 Jul;180(1):352-60
references.pmid: 18499163
references.citation: Science. 2008 Aug 22;321(5892):1084-5
references.pmid: 18719283
references.citation: Nucleic Acids Res. 2003 Aug 1;31(15):4481-9
references.pmid: 12888508
references.citation: Cancer Res. 2001 Oct 15;61(20):7464-72
references.pmid: 11606381
references.citation: Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005247
references.pmid: 17054249
references.citation: Cancer Gene Ther. 2005 Aug;12(8):715-22
references.pmid: 15832172
references.citation: Oncogene. 1998 Jan 22;16(3):311-20
references.pmid: 9467956
references.citation: EMBO J. 2004 May 5;23(9):1949-56
references.pmid: 15071503
references.citation: Nucleic Acids Res. 2007;35(20):e138
references.pmid: 17965092
references.citation: Gene Ther. 2008 May;15(9):635-51
references.pmid: 18273054
references.citation: Urology. 2007 Dec;70(6):1243-8
references.pmid: 18158069
references.citation: J Virol. 2004 Dec;78(23):12868-76
references.pmid: 15542639
references.citation: Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14590-5
references.pmid: 9405657
references.citation: Mol Biol Cell. 1999 Jul;10(7):2119-29
references.pmid: 10397753
references.citation: Cancer Res. 1999 Sep 1;59(17):4200-3
references.pmid: 10485454
references.citation: Mol Cell Biol. 1998 Jan;18(1):629-43
references.pmid: 9418909
references.citation: Clin Cancer Res. 2009 Mar 1;15(5):1730-40
references.pmid: 19223497
references.citation: Am J Physiol Lung Cell Mol Physiol. 2009 Mar;296(3):L361-71
references.pmid: 19112102
references.citation: Biochem Biophys Res Commun. 1996 Aug 23;225(3):759-63
references.pmid: 8780686
references.citation: Cancer Gene Ther. 2009 Nov;16(11):810-9
references.pmid: 19407849
references.citation: Gene Ther. 2003 Nov;10(23):1982-91
references.pmid: 14528322
references.citation: Kidney Int. 1998 Feb;53(2):264-72
references.pmid: 9461084
references.citation: Mol Ther. 2007 Aug;15(8):1495-503
references.pmid: 17565351
references.citation: Cancer Res. 2002 Aug 15;62(16):4663-70
references.pmid: 12183423
references.citation: Science. 1996 Oct 18;274(5286):373-6
references.pmid: 8832876
references.citation: Science. 2008 Aug 22;321(5892):1086-8
references.pmid: 18719284
references.citation: Genome Biol. 2007;8(4):R58
references.pmid: 17430596
references.citation: Cell. 1993 Nov 5;75(3):477-86
references.pmid: 8221887
references.citation: Nat Med. 2005 Jan;11(1):77-84
references.pmid: 15619633
references.citation: Front Biosci. 2002 May 01;7:d1369-95
references.pmid: 11991831
references.citation: Hum Gene Ther. 2005 May;16(5):618-26
references.pmid: 15916486
references.citation: EMBO J. 1994 Nov 1;13(21):5075-85
references.pmid: 7957073
references.citation: Mol Ther. 2006 Jul;14(1):107-17
references.pmid: 16690359
references.citation: Mol Cell Biol. 1998 May;18(5):2845-54
references.pmid: 9566903
references.citation: Cancer Res. 1997 Jul 1;57(13):2559-63
references.pmid: 9205053
references.citation: Br J Cancer. 2006 Jun 19;94(12):1837-44
references.pmid: 16736005
references.citation: J Virol. 1991 Nov;65(11):5657-62
references.pmid: 1920611
references.citation: Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14
references.pmid: 9482916
references.citation: Am J Physiol Lung Cell Mol Physiol. 2007 Mar;292(3):L716-24
references.pmid: 17085526
references.citation: Cell Death Differ. 2000 Aug;7(8):721-8
references.pmid: 10918446
references.citation: Proc Natl Acad Sci U S A. 1979 Aug;76(8):3665-9
references.pmid: 291030
references.citation: Gene Ther. 2008 Apr;15(7):484-94
references.pmid: 18239605
references.citation: J Virol. 2001 Oct;75(20):9844-56
references.pmid: 11559818
references.citation: Cancer Res. 2001 Oct 15;61(20):7544-51
references.pmid: 11606392
references.citation: Gene Ther. 2005 Jun;12(11):902-10
references.pmid: 15690062
references.citation: Cancer Res. 2002 May 1;62(9):2576-82
references.pmid: 11980652
references.citation: Mol Ther. 2006 Dec;14(6):768-78
references.pmid: 16990052
references.citation: Cancer Gene Ther. 2004 Jul;11(7):477-86
references.pmid: 15118762